Low Testosterone Levels Linked to Sixty Percent Higher Risk of Aggressive Prostate Cancer Progression

New MD Anderson research finds low testosterone increases the risk of prostate cancer progression by 60 percent, offering a new marker for patient surveillance.

By: AXL Media

Published: Mar 10, 2026, 11:39 AM EDT

Source: The information in this article was sourced from University of Texas M. D. Anderson Cancer Center

Hormonal Markers Redefine Risk for Prostate Cancer Surveillance

Clinical data from the University of Texas MD Anderson Cancer Center has revealed a startling correlation between low testosterone and the acceleration of early stage prostate cancer. Researchers discovered that patients maintaining testosterone levels at or below 300 ng/dl were 60 percent more likely to see their condition transition into a more aggressive state while under active surveillance. This finding provides a new lens through which urologists can view the biological behavior of low risk tumors, moving beyond traditional indicators like tumor size to include the patient's internal hormonal environment.

Challenging the Traditional Narrative of Testosterone and Tumor Growth

For decades, the prevailing medical consensus suggested that high levels of testosterone acted as a primary fuel for the proliferation of prostate cancer cells. However, this new research, published in The Journal of Urology, turns that long held belief on its head by demonstrating that it is actually a deficiency in the hormone that correlates with disease progression. By analyzing more than 900 men, the study suggests that a low hormonal baseline may create an environment where cancer is more likely to reach Grade Group 3 or higher, which signifies a much more dangerous and harder to treat form of the disease.

Strategic Utility of Baseline Testing in Clinical Practice

The ability to predict which patients will remain stable and which will face rapid progression is the primary challenge of modern urology. According to Justin R. Gregg, M.D., an associate professor of Urology and Health Disparities Research, identifying these high risk individuals is essential for refining how doctors manage active surveillance. By incorporating a simple baseline testosterone test into the initial diagnostic workup, clinicians may be able to stratify patients more accurately, ensuring that those with low hormonal levels receive closer scrutiny or earlier intervention than those with normal ranges.